meto
Log in
Peptide

Tesamorelin

A stabilised GHRH analog with FDA approval for visceral-fat reduction in HIV-associated lipodystrophy — increasingly used off-label for metabolic syndrome.

Definition

Tesamorelin is a synthetic GHRH analog with a stabilising trans-3-hexenoic acid modification on the native human GHRH sequence. It binds the pituitary GHRH receptor with high affinity and extended half-life.

How Meto uses it.

Availability: Available solo and in the SCULPT body-composition formulation (awaiting FDA regulatory action). Dosing: 1–2 mg subcutaneous nightly, 5 nights on / 2 off. A typical cycle runs six months with visceral-fat imaging (DEXA or equivalent) at baseline and month three. Monitoring: IGF-1, fasting glucose and HbA1c are re-checked on the same cadence.

Safety notes

  • Contraindicated in active malignancy and pituitary tumour history
  • Contraindicated in uncontrolled diabetes and retinopathy
  • Not for use in pregnancy or lactation
  • Injection-site reactions are the most common side effect — rotate sites
  • Fluid retention can occur during initiation; typically resolves by week 4

Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.

Common questions

Tesamorelin vs. Sermorelin — what's the difference?

Tesamorelin is the native human GHRH sequence stabilised for pharmaceutical use — it has the strongest RCT evidence in visceral fat. Sermorelin is the native 1–29 fragment: shorter-acting, gentler.

How much visceral fat reduction should I expect?

The NEJM 2010 trial showed roughly 15–18% visceral-adipose-tissue reduction at 26 weeks.

Can I use it with a GLP-1?

Yes, but only with clinician oversight. Both affect glucose handling in different ways.

PreviousTelomereClinical ConceptNextTestosteroneBiomarker

Read More

Mechanism

GHRH AnalogGrowth-Hormone-Releasing Hormone Analog

A class of peptides that mimic growth-hormone-releasing hormone at the pituitary to trigger the body's own GH release — CJC-1295, Tesamorelin and Sermorelin.

Peptide

Sermorelin

A native GHRH analog — the gentlest and most-studied entry point into growth-hormone-axis therapy.

Clinical Concept

Visceral FatVisceral Adipose Tissue

Fat stored around internal organs — metabolically active, tied to cardiovascular risk, and the target of Tesamorelin and SCULPT.

$149 panel.
A clinician reads it in 24 hours.

Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.

Start with labs · $149